SI delivered the week's defining moment after Tuesday's close — a Q1 earnings beat that sent the company's FY2026 sales guidance sharply higher, creating a sharp contrast with the month-long share price slide leading into the print.
The numbers from Q1 were a tale of two metrics. Revenue of $16.7 million comfortably beat the $14.5 million consensus estimate, and management followed with a guidance raise that lifted the full-year sales range to $65–$68 million, up from $62–$65 million, versus a Street expectation of $64.1 million. At the same time, EPS came in at –$0.41, just a penny short of the –$0.40 estimate. The company is burning cash while scaling, which is the expected profile for a growth-stage medical device name. The read is straightforward: the top line is tracking ahead of plan even if profitability is not yet.
The positioning picture coming into earnings was anything but stretched. Short interest was running at a modest 2.1% of the free float — not a level that warrants alarm — and had barely moved over the week, with estimated shares short edging up just 0.6% over the past five days. Borrow remains easy: cost to borrow is 1.19%, creeping up roughly 10% over the week but still well below the 1.45% levels seen in mid-April. Availability is ample, with only about 28% of the lending pool currently in use against a 52-week peak of 51%. The market was not set up for a squeeze and there was no unusual short pressure heading into the result.
Analyst sentiment is constructive, and the guidance raise strengthens the bull case. Piper Sandler moved first this week, raising its target to $19 from $18 and reiterating Overweight just ahead of the print — a signal the firm had confidence in the quarter. The broader analyst group remains aligned: coverage carries a buy consensus, with the mean target at $20.50, implying roughly 53% upside from the current $13.37. BTIG and Goldman have both held buy-equivalent ratings with targets in the $20–$24 range, though the Goldman and Morgan Stanley initiations are now roughly nine months old. The bull case centers on surgeon adoption — core-contender customers grew ~61% year-over-year — while bears point to the EBITDA burn, which came in at –$23.6 million on a full-year basis and exceeded model estimates by a meaningful margin. The stock is down 10.6% over the past month and off 6.5% year-to-date, so the price hadn't been pricing in much good news ahead of Tuesday.
Insider conviction has been consistent and worth noting. In March, both the CEO Rob Ball and CFO Jeff Points bought shares on the open market at prices around $15, just as the stock was trading above current levels. The net insider position over the 90-day window through mid-March was +12,206 shares, worth roughly $181,000. That pattern holds back through December, when Ball and Points each added to positions at similar prices. The company's largest holders — FMR (Fidelity) at 18.6% and USVP Management at 13% — have been stable, while BlackRock quietly added nearly 108,000 shares as of April 30, reflecting growing passive-flow interest as the company's market cap edges toward index thresholds.
The most recent confirmed prior-quarter print (April 17) showed the stock moving +5.5% on earnings day before giving back ground to –8.1% over the following five sessions, a reminder that initial reactions in thin micro-cap names can be reversed quickly. Next earnings is flagged for late June. In the near term, attention will focus on whether the Q1 sales beat and guidance raise are enough to close the gap between the $13.37 current price and the $20.50 analyst target — or whether continued EBITDA losses keep a ceiling on re-rating.
See the live data behind this article on ORTEX.
Open SI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
